Cargando…
Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib
Cervical cancer is caused by high-risk human papillomavirus (HPV) types and treated with conventional chemotherapy with surgery and/or radiation. HPV E6 and E7 proteins increase phosphorylation of retinoblastoma (Rb) by cyclin D1/cyclin dependent kinase (CDK)4/6 complexes. We hypothesized that cycli...
Autores principales: | Kennedy, Amy L., Rai, Rajani, Isingizwe, Zitha Redempta, Zhao, Yan Daniel, Lightfoot, Stanley A., Benbrook, Doris M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281234/ https://www.ncbi.nlm.nih.gov/pubmed/32429557 http://dx.doi.org/10.3390/cancers12051269 |
Ejemplares similares
-
Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
por: Chandra, Vishal, et al.
Publicado: (2021) -
Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2
por: Rai, Rajani, et al.
Publicado: (2022) -
SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention
por: Benbrook, Doris Mangiaracina
Publicado: (2022) -
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
por: Myers, Tashanna, et al.
Publicado: (2008) -
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2
por: Sharma, Ankur, et al.
Publicado: (2018)